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Abstract  
There is a large individual variation in the bone remodelling markers (BRMs) osteocalcin (OC), 
procollagen 1 N-terminal propeptide (P1NP) and β-isomerized C-terminal telopeptide (β-CTx), 
as well as undercarboxylated osteocalcin (ucOC), at rest and in response to exercise. ACTN3, 
sarcomeric protein, gene is expressed in skeletal muscle and osteoblasts, and may influence 
BRM levels and the cross-talk between muscle and bone. We tested the levels of serum BRMs 
in α-actinin-3 deficient humans (ACTN3 XX) at baseline, and following a single bout of 
exercise. Forty three healthy Caucasian individuals were divided into three groups (ACTN3 
XX, n=13; ACTN3 RX (haploinsufficient), n=16; ACTN3 RR, n=14). Participants completed a 
single session of High Intensity Interval Exercise (HIIE) on a cycle ergometer (8×2-min 
intervals at 85% of maximal power). Blood samples were taken before, immediately after, and 
three hours post exercise to identify the peak changes in serum BRMs. There was a stepwise 
increase in serum BRMs across the ACTN3 genotypes (XX>RX>RR) with significantly higher 
levels of tOC ~26%, P1NP ~34%, and β -CTX ~33%) in those with ACTN3 XX compared to 
ACTN3 RR. Following exercise BRMs and ucOC were higher in all three ACTN3 genotypes, 
with no significant differences between groups.  
Serum levels of tOC, P1NP and β-CTX are higher in men with ACTN3 XX genotype (α-actinin-
3 deficiency) compared to RR and RX. It appears that the response of BRMs and ucOC to 
exercise is not explained by the ACTN3 genotype. 
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Introduction 
Skeletal health is maintained throughout life by the cellular machinery of bone remodelling, 
the final common pathway mediating the effects of all genetic and environmental factors on 
the material composition, microstructure and strength of bone [1]. Bone remodelling is 
challenging to assess in vivo and as consequences, surrogate measures in the serum, known 
collectively as bone remodelling markers (BRMs), are commonly used. Common serum BRMs 
include osteocalcin (OC), procollagen 1 N-terminal propeptide (P1NP), and β-isomerized C-
terminal telopeptide (β-CTX) [2]. Higher levels of serum BMRs have been associated with 
higher bone turnover [3]. 
Exercise is an important, non-pharmacological intervention that improves bone health and 
reduces the risk of osteoporosis and also improves glucose regulation and insulin sensitivity 
[4,5]. The above mentioned effects of exercise are partly via the undercarboxylated form of 
osteocalcin (ucOC) [6]. Even a single bout of exercise can increase circulating levels of BRMs 
and ucOC, and can improve insulin sensitivity [6-8]. However, we, and others, have reported 
large individual variability for the changes in BRMs and ucOC in response to similar exercise 
[9,6,7,10,8,11]. Indeed, some individuals are ‘low-responders’ (do not increase some aerobic-
related traits in response to exercise training), while others respond well or very well (‘high-
responders’) to similar exercise, and this is, at least partly, likely due to genetic variability [12]. 
One gene that has been shown to have an association with the response to exercise training in 
humans [13] and mice [14] is ACTN3, which encodes for the sarcomeric protein α-actinin-3 in 
skeletal muscle fibres. Homozygosity for a common null single nucleotide polymorphism 
(ACTN3 R577X, rs1815739) in the ACTN3 gene results in complete deﬁciency of the α-actinin-
3 protein (ACTN3 XX genotype) in an estimated 18% of humans worldwide, whereas 
individuals with the ACTN3 RR or RX (haploinsufficinet) genotypes express the α-actinin-3 
protein[15]. We, and others, have established an association between the ACTN3 R577X 
genotype and athletic performance. It appears that the ACTN3 XX genotype is associated with 
increased aerobic performance ([16,17]whereas the RR genotype is more prevalence in 
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sprint/power athletes [13,18].Importantly, ACTN3 is also expressed in osteoblasts, the bone 
forming cells - the same cells that produce and secrete OC and ucOC, and therefore may 
influence BRM levels and the cross-talk between muscle and bone [19]. The ACTN3 XX 
genotype has been associated with reduced muscle mass in the elderly [20], and with an 
increased risk of falling in post-menopausal women [21]. Recently, it has been shown that α-
actinin-3-deficient mice (Actn3 knockout mice, mimicking the ACTN3 XX genotype in 
humans) exhibit lower bone mineral density and bone formation rates per unit bone surface 
(BFR/BS) compared to wild type (WT) littermates, partly due to altered osteoblastic function 
[19]. Although not investigated to date, this suggests ACTN3 genotype might influence basal 
and exercise-induced serum BRM levels. 
As such, the aims of the current study were:  A) to test the hypothesis that α-actinin-3 deficient 
men (ACTN3 XX genotype) have higher levels of serum BRMs compared to men with ACTN3 
RR or RX;  and B) to test the hypothesis that BRMs and ucOC, which has been implicated in 
glucose regulation and insulin sensitivity [6,22], will increase to a greater degree following 
exercise in individuals with the ACTN3 XX genotype, compared to those with ACTN3 RR and 
RX. 
 
Materials and Methods   
Participants: Forty-three young, healthy, Caucasian men were given written and verbal 
explanations about the study before signing an informed consent form. The study protocol was 
approved by the Human Research Ethics Committee, Victoria University. The study is part of 
the Genes and Skeletal Muscle Adaptive Response to Training (Gene SMART) study 
(www.vu.edu.au/speed-gene), which aims to discover genetic variants that influence health-
related phenotypes. A detailed medical history was assessed by questionnaire. Participants with 
bone disease, taking hypoglycaemic medications, or medications known to affect bone 
metabolism, insulin secretion or insulin sensitivity, musculoskeletal or other conditions that 
prevent daily activity, or receiving warfarin or vitamin K supplementation, were excluded from 
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the study. Flow diagram of recruitment is illustrated in Figure 1. 
Peak aerobic capacity (VO2peak): VO2peak was assessed using a graded exercise test (GXT). 
This test was performed on an electronically-braked cycle-ergometer (Lode-excalibur sport, 
Groningen, the Netherlands), and consisted of 4-min stages separated by 30-s rest periods until 
voluntary exhaustion. VO2peak was measured using a calibrated Quark CPET metabolic system 
(COSMED, Rome, Italy). The high intensity interval exercise (HIIE) phase commenced 48 - 
72 h after the GXT. Capillary blood samples were collected prior to the GXT test. 
Genotyping: Genomic DNA was extracted from residual capillary blood samples from the GXT 
tests using the GeneJET Genomic Whole Blood DNA Purification Kit (#K0781 Thermo 
Scientific, MA, USA). Candidate gene variants were determined using the TaqMan SNP assay 
(rs1815739 Cat. # 4351379, Life Technologies Australia), by Mastercycler® ep realplex2 
(Eppendorf, Hamburg, Germany). Genotyping was replicated in another institute, as previously 
described [23] to validate the results. Participants were then divided into three groups according 
to their ACTN3 genotype (ACTN3 XX, N=13; ACTN3 RX, N=16; ACTN3 RR, N=14, Table 1). 
Nutrition consultation: Prior to the HIIE each participant was provided with individualised, 
pre-packaged meals for the 48 h prior to the resting blood sample. The content of the diets are 
constructed based on the current National Health and Medical Research Council (NHMRC) 
guidelines. Participants were asked not to eat any food and avoid caffeine and alcohol 12 h 
prior to the HIIE phase and the blood collection.  
HIIE phase: Participants completed a single session of High Intensity Interval Exercise (HIIE) 
on a cycle ergometer (8×2-min intervals at 85% of peak aerobic power, with 1 min of recovery 
between intervals). Peak aerobic power was set as the highest watts (Wpeak) the participants 
paddled against in the final stage of the GXT. Venous blood samples were collected, by 
venepuncture or cannulation, before, immediately after, and three hours post exercise, to 
identify the peak change in BRMs. Five millilitres of venous blood were stored in BD 
Vacutainer SST ®  II ™ tubes (Becton, Dickinson and Company, USA), inverted 6-10 times, 
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centrifuged at 3,500 rpm for 10 minutes at 4 ˚C, and subsequently analyses for BMRs was 
performed. 
Bone remodelling marker (BRMs) assays 
Serum osteocalcin and undercarboxylated osteocalcin: Total serum OC was measured using 
an automated immunoassay (Elecsys 170; Roche Diagnostics). This assay has a sensitivity of 
0.5μg·L-1, with an intra-assay precision of 1.3%. Serum ucOC was measured by the same 
immunoassay after adsorption of carboxylated OC on 5 mg/mL hydroxyl-apatite slurry, 
following the method described by Gundberg et al.[24]   
β-CTX and P1NP:  β-isomerized C-terminal telopeptide (β-CTX, bone resorption marker) and 
procollagen I N-terminal propeptide (P1NP, a bone formation marker) were analysed at Austin 
pathology, Melbourne using a Roche Hitachi Cobas e602 immunoassay analyser, according to 
the manufacturer’s guidelines. 
Statistical analysis 
A multivariate analysis with a post-hoc, LSD, correction was used to identify differences 
between the three groups at baseline and to compare the percentage change following acute 
exercise between groups. A paired t test was used to identify changes within group relative to 
baseline in response to a single bout of exercise. Multi-linear regression Backward model with 
age, BMI and aerobic fitness were used to determine association with BRMs. All data are 
reported as mean ± standard error of mean (SEM) and all statistical analyses were conducted 
at the 95% level of significance (p≤0.05). 
Results 
Genotype groups (XX, RX and RR) were matched for age, BMI and aerobic capacity (p>0.05, 
Table 1). At baseline, there was a stepwise increase in the circulating levels of tOC (Figure 
2A), P1NP (Figure 2C) and β-CTX (Figure 2 D) between ACTN3 genotypes (XX, RX and RR). 
Individuals with ACTN3 XX had a higher tOC (∼26%, p <0.05), P1NP (∼34%, p <0.05,) and 
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β-CTX (∼33%, p <0.05), compared to those with ACTN3 RR (p<0.05). ucOC was similar 
across genotypes (all p > 0.37, Figure 1B).  
Multiple regression analysis: in all three ACTN3 genotypes (RR, RX and XX), age, but not 
BMI or aerobic power, was the strongest predictor for tOC (β= -0.72, p=0.004; β= -0.77, 
p=0.001 and β= -0.70, p=0.008, respectively), ucOC (β= -0.48, p=0.055; β= -0.73, p=0.001 
and (β= -0.39, p=0.19, respectively), P1NP (β= -0.77, p=0.001; β= -0.69, p=0.003 and β= -
0.79, p=0.001, respectively) and β-CTX (β= -0.62, p=0.019; β= -0.84, p<0.001 and β= -0.67, 
p=0.013, respectively). 
Effect of exercise: Overall, participants in all three ACTN3 genotypes responded similarly to a 
single session of HIIE. There were no differences between groups in response to HIIE with the 
exception of tOC between ACTN3 RX and ACTN3 XX (p=0.02, Figure 3). Compared to 
baseline, individuals with ACTN3 RX exhibited an increase in tOC, ucOC, P1NP and β-CTX 
(9-15%, p<0.05) following a single bout of HIIE (Figure 3). Individuals with ACTN3 XX 
exhibited a significant increase in ucOC and P1NP (p<0.05). However, no significant 
difference was noted for β-CTX (∼7%, p=0.104, Figure 3) following HIIE in these individuals. 
Individuals with ACTN3 RR, exhibited an increase in P1NP (p<0.001). However, no significant 
differences were noted for ucOC and β-CTX (∼7% and ∼5%  p<0.12, respectively, Figure 3) 
following HIIE.  
Multiple regression analysis following exercise: In participants with the ACTN3 RR and the 
ACTN3 RX, age, BMI or VO2peak did not predict the change in tOC, ucOC, P1NP or β-CTX 
following exercise. In participants with the ACTN3 XX, age, BMI or VO2peak did not predict 
the change in tOC. However, VO2peak, but not age or BMI, predicted exercise-induced change 
in ucOC (β= 0.57, p=0.04) and tended to predict changes in β-CTX (β= -0.51, p=0.073) 
following exercise.       
 
Discussion 
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We reported that there was a stepwise increase in baseline tOC, P1NP and β-CTX across the 
ACTN3 genotypes (XX>RX>RR). This may indicate that α-actinin-3 -deficient individuals 
(ACTN3 XX genotype) have higher bone turnover at rest compared to ACTN3 haploinsufficient 
RX and normally expressing RR individuals. However, resting ucOC levels and the response 
of serum BRMs and ucOC to exercise is not explained by the ACTN3 R577X gene variant; the 
magnitude of exercise-induced increase in circulating BRMs and ucOC was similar regardless 
of ACTN3 genotype.  
The ACTN3 gene is expressed in bone and fast glycolytic (Type 2X) skeletal muscle fibres, 
and Actn3 KO mice have lower bone mineral density, lower bone mass, lower trabecular bone 
volume and reduced BFR/BS compared to WT littermates [19]. Similarly, older women with 
deficiency in α-actinin-3 (ACTN3 XX genotype) have lower bone mineral density [19]. In the 
current study we report a stepwise increase in tOC, P1NP and β-CTX across the ACTN3 
genotypes, and individuals with the ACTN3 XX genotype were characterised with the highest 
levels of BRMs and ACTN3 RR the lowest. These findings in healthy young men are in 
agreement with those reported previously in older women [19], and may have practical and 
clinical implications. For instance, elite endurance athletes (i.e., long-distance runners) have a 
higher frequency of the ACTN3 XX genotype compared to the general population [16,17]. 
However, long distance runners, both males and females, also have lower bone mineral density 
and a higher bone turnover that increases the risk of stress fracture [25-27]. Deficiency of α-
actinin-3 has also been associated with reduced muscle mass in the elderly [28,20], and with 
an increased risk of falling in post-menopausal women [21]. As such, individuals with the 
ACTN3 XX genotype may also be at a higher risk of future osteopenia or osteoporosis. 
Importantly, in the current study, individuals with ACTN3 XX had higher tOC, P1NP and β-
CTX, compared to their ACTN3 RR counterparts despite the fact that they were recreationally 
active, not involved in elite sport, and the genotypes (XX, RX and RR) were matched for age, 
BMI and aerobic capacity. These data suggest that individuals with the ACTN3 XX genotype 
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may be prone to higher BRMs, and greater future bone loss, compared to RR, independent of 
other confounding factors. We note that bone density and bone micro-architecture were not 
assessed in the current study, and future studies should examine the effect of ACTN3 XX on 
bone structure over time.  
In humans, ucOC, and tOC, are correlated with insulin sensitivity, fasting glucose and muscle 
strength [29-32]. As such, it is possible that higher circulating levels of ucOC enhance glucose 
metabolism in skeletal muscle. However, it appears that the ACTN3 genotype plays little or no 
role in the levels of circulating serum ucOC, and, as such, ACTN3 genotypes may not have a 
direct effect on glucose metabolism. It has been reported that the prevalence of the ACTN3 XX 
genotype is higher, and not lower, as expected, in patients with type 2 diabetes; however, the 
genotype distribution was unrelated to metabolic control or obesity [33].  Although ACTN3 
genotype does not appear to influence metabolic control in type 2 diabetic individuals, Riedl 
et al. proposed that ACTN3 genotype may influence glucose metabolism indirectly via effects 
on sarcomeric proteins and muscle function [33] . 
Acute exercise increases ucOC, and this increase in ucOC is associated with a reduction in 
serum glucose levels in obese men [10].  In contrast to our hypothesis, participants BRMs 
responded similarly to HIIE regardless of their ACTN3 genotype. However, the mean change 
in tOC was greatest in the ACTN3 RX group. The overall findings highlight that, in men, serum 
BRMs increase following exercise independent of ACTN3 genotype, and individual variation 
in response to exercise is not solely related to the ACTN3 R577X polymorphisms. As such, 
future studies should examine other genetic variations or other factors that may affect 
individual responses to exercise. 
A potential limitation of the study is the relatively small sample size in each genotype. Yet, 
significant differences were observed between individuals with different ACTN3 genotypes at 
rest and within groups in response to exercise. Furthermore, the trial was tightly-controlled in 
terms of aerobic capacity, the exercise stimulus and nutrition; thus, we are confident that our 
findings reflect the influence of the ACTN3 genotype on the described phenotypes.  
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In conclusion, there was a stepwise increase in tOC, P1NP and β-CTX across the ACTN3 
genotypes (XX>RX>RR) in young men; ACTN3 XX genotype is associated with higher basal 
levels of serum BRMs. It appears that the response of BRMs and ucOC to exercise is not 
explained by the ACTN3 genotype. Future studies should explore the mechanism/s behind the 
influence of this variant on BRMs, and should also explore other genes or factors that may 
explain different individual responses following exercise. 
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Figure 1. Flow diagram of recruitment. 
 
 
Figure 2. Comparison of serum bone remodelling markers (BRMs) and ucOC in men across 
the ACTN3 genotypes. Total osteocalcin (tOC, A), uncarboxylated osteocalcin (ucOC, B), 
procollagen 1 N-terminal propeptide (P1NP, C) and β-isomerized C-terminal telopeptides (β-
CTx, D).  * p<0.05, ^ p= 0.09. 
 
Figure 3. The influence of ACTN3 genotype on the acute response of serum BRMs to High 
Intensity Interval Exercise (HIIE). * p< 0.05, ** p<0.01 compared to baseline levels. & 
indicates p<0.05 between genotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
